Evropská unie - čeština - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastická činidla - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Evropská unie - čeština - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Evropská unie - čeština - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplasmy prsů - antineoplastická činidla - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Evropská unie - čeština - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

ardez pharma, spol. s r.o., kosoř array - 1456 kyselina thioktovÁ - potahovaná tableta - 600mg - kyselina thioktovÁ

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

viatris healthcare limited, dublin array - 14912 trometamol-tioktÁt - injekční roztok - 600mg - kyselina thioktovÁ

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

viatris healthcare limited, dublin array - 1456 kyselina thioktovÁ - potahovaná tableta - 600mg - kyselina thioktovÁ

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 1456 kyselina thioktovÁ - potahovaná tableta - 600mg - kyselina thioktovÁ

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

wörwag pharma gmbh & co. kg, böblingen array - 1456 kyselina thioktovÁ - potahovaná tableta - 600mg - kyselina thioktovÁ

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

wörwag pharma gmbh & co. kg, böblingen array - 19446 thioktÁt-meglumin - infuzní roztok - 600mg - kyselina thioktovÁ